Elsevier

Gastrointestinal Endoscopy

Volume 84, Issue 6, December 2016, Pages 924-929
Gastrointestinal Endoscopy

Original article
Clinical endoscopy
A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors

https://doi.org/10.1016/j.gie.2016.04.019Get rights and content

Background and Aims

Accurate diagnosis of small gastric subepithelial tumors (SETs) is essential to assess their malignant potential. Endoscopic unroofing has been reported to yield sufficient tissue samples for histologic evaluation. This study aimed to evaluate the safety, diagnostic yield, and potential therapeutic effects of this technique over time.

Methods

This retrospective analysis of prospectively collected clinical data identified patients who underwent endoscopic unroofing at the Medical University of Vienna from January 2003 to December 2012. Demographic data, indications for endoscopic unroofing, intraprocedural adverse events, hospital stay, histologic results, and follow-up procedures were reviewed.

Results

A total of 14 patients (7 men; 7 women; median age, 70 years; range, 51-95 years) underwent endoscopic unroofing of 14 gastric SETs with a mean diameter of 26 ± 13 mm at EUS. In 9 of 14 cases, endoscopic unroofing was done exclusively for diagnostic purposes; in the remaining cases, it was performed with therapeutic intent because of bleeding from the gastric SETs. Unroofing was technically successful in 13 of 14 cases and revealed 8 cases of GI stromal tumor (GIST) and 1 case each of leiomyoma, fibroid polyp, glomus tumor, pancreatic rest, and nondiagnostic material at histology. Intraprocedural bleeding was the only adverse event (4 cases) and could be managed endoscopically. A follow-up EUS was available (median, 8 months) for 10 of the 14 patients. Notably, most patients showed complete regression of their gastric SETs after unroofing (on white light and EUS), including the glomus tumor, the leiomyoma, and 6 of the 8 cases of GIST.

Conclusions

Endoscopic unroofing was safe and had a very favorable diagnostic yield in this study. Unexpectedly, it led to complete regression in most gastric SETs. Although it is not an oncologically curative treatment, endoscopic unroofing can be a valuable option to treat local adverse events in patients unfit for surgical therapy. (Clinical trial registration number: NCT02587923.)

Section snippets

Materials and methods

This retrospective study of prospectively collected clinical data was conducted at the Division of Gastroenterology and Hepatology, Department of Internal Medicine III of the Medical University of Vienna, a tertiary academic referral center for Vienna and eastern Austria. The study protocol was approved by the internal review board of the Medical University of Vienna (EK 1707/2015) and registered at clinicaltrials.gov (NCT02587923). Patients who underwent endoscopic unroofing of gastric SETs

Results

Within the study period, a total of 14 patients (7 men; 7 women; median age, 70 years; range, 51-95 years) underwent endoscopic unroofing of 14 gastric SETs. The mean diameter of the subepithelial lesions was 26 ± 13 mm at endosonography (range of maximum diameters. 10-60 mm). Most lesions had arisen from the muscularis propria layer. In most cases (9/14), endoscopic unroofing was done exclusively for diagnostic purposes (including 3 patients who had already undergone EUS-FNA with a

Discussion

This is the first study to systematically investigate endoscopic unroofing for gastric SETs with regard to safety, diagnostic yield, and therapeutic effect over time. The technique proved to be feasible in almost all cases and showed a very favorable safety profile. The diagnostic yield was excellent because the specimens were big enough for a detailed histopathologic assessment, including mitotic analysis and immunohistochemistry. The most surprising result came from follow-up examinations:

References (16)

There are more references available in the full text version of this article.

DISCLOSURE: All authors disclosed no financial relationships relevant to this publication.

If you would like to chat with an author of this article, you may contact Dr Dolak at [email protected].

View full text